Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The *pre-S2 domain* is a 55-amino acid region found within the middle (MHBs) and large (LHBs) envelope proteins of hepatitis B virus. HBsAg proteins are essential for virus particle assembly, morphogenesis, and infectivity. The pre-S2 domain acts mainly as a structural spacer, supporting proper folding and capsid binding during viral envelope formation[3][5]. Mutations in the pre-S2 region can facilitate immune escape and affect serological detection[5]. The surface antigen proteins, containing pre-S2, are key diagnostic biomarkers and targets for both vaccination and therapeutic intervention. Drug interactions occur primarily through neutralizing antibody recognition or, in the case of entry inhibitors, through the NTCP receptor rather than direct pre-S2 targeting. Pre-S2 mutants have been associated with adverse liver disease outcomes and may complicate therapy or disease monitoring[1][5][7].
Inhibition of viral entry by blocking envelope protein-receptor interaction (e.g., NTCP) Neutralization of virus via antibody binding to HBsAg containing pre-S2 domains
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus large surface protein (pre-S2 domain) (null).